AstraZeneca PLC — Regulatory Filings 2020

Mar 20, 2020

6-K 1 a8885g.htm DIRECTOR/PDMR SHAREHOLDING Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com Copyright 2020 Issuer Direct Corporation a8885g

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of March 2020

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_______

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Director/PDMR Shareholding

20 March 2020 07:00 GMT

Transaction by Person Discharging Managerial Responsibilities

Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announced that, on 19 March 2020, it was notified by Tony Mok, a Non-Executive Director of the Company, that, on 18 March 2020, Mr Mok purchased 1,000 of the Company's American Depositary Shares (ADSs) at a price of $38.32 per ADS. Two ADSs are equivalent to one Ordinary Share of $0.25 in the Company.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

| 1 — a) | Details of the person discharging managerial responsibilities /
person closely associated — Name | Tony
Mok | |
| --- | --- | --- | --- |
| 2 | Reason for the notification | | |
| a) | Position/status | Non-Executive
Director | |
| b) | Initial notification /Amendment | Initial
notification | |
| 3 | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | AstraZeneca
PLC | |
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted | | |
| a) | Description of the financial instrument, type of
instrument Identification
code | AstraZeneca PLC American Depositary Shares CUSIP: 046353108 | |
| b) | Nature of the transaction | Purchase
of AstraZeneca PLC American Depositary Shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | US$38.32 | 1,000 |
| d) | Aggregated information - Aggregated volume - Price | Not applicable - single transaction | |
| e) | Date of the transaction | 18
March 2020 | |
| f) | Place of the transaction | NYSE | |

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @ AstraZeneca .

| Media
Relations — Gonzalo
Viña | | +44 203
749 5916 |
| --- | --- | --- |
| Rob
Skelding | Oncology | +44 203
749 5821 |
| Rebecca
Einhorn | Oncology | +1 301
518 4122 |
| Matt
Kent | BioPharmaceuticals | +44 203
749 5906 |
| Angela
Fiorin | BioPharmaceuticals | +44
1223 344 690 |
| Jennifer
Hursit | Other | +44
203 749 5762 |
| Christina Malmberg
Hägerstrand | Sweden | +46 8 552 53 106 |
| Michele
Meixell | US | +1 302
885 2677 |
| Investor
Relations | | |
| Thomas
Kudsk Larsen | | +44 203
749 5712 |
| Henry
Wheeler | Oncology | +44 203
749 5797 |
| Christer
Gruvris | BioPharmaceuticals (Cardiovascular,
Metabolism) | +44 203
749 5711 |
| Nick
Stone | BioPharmaceuticals
(Renal) Environmental, Social and Governance | +44 203
749 5716 |
| Josie
Afolabi | BioPharmaceuticals
(Respiratory) | +44 203
749 5631 |
| Tom
Waldron | Other
medicines | +44
7385 033 717 |
| Craig
Marks | Finance Fixed
income | +44
7881 615 764 |
| Jennifer
Kretzmann | Corporate
access Retail
investors | +44 203
749 5824 |
| US
toll-free | | +1 866
381 72 77 |

Adrian Kemp

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 20 March 2020

| By: /s/
Adrian Kemp |
| --- |
| Name:
Adrian Kemp |
| Title:
Company Secretary |

page break